Literature DB >> 901709

A rapid method for the determination of plasma mexiletine levels by gas chromatography.

I D Bradbrook, C James, H J Rogers.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 901709      PMCID： PMC1429072          DOI： 10.1111/j.1365-2125.1977.tb00730.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  4 in total

1.  Preliminary studies on the pharmacology of an antidysrhythmic, Kö 1173, in man.

Authors:  M A Kiddie; R B Royds; T R Shaw
Journal:  Br J Pharmacol       Date:  1973-03       Impact factor: 8.739

2.  Spectrophotofluorometric and gas-liquid chromatographic methods for the estimation of mexiletine (Kö 1173) in plasma and urine.

Authors:  J G Kelly; J Nimmo; R Rae; R G Shanks; L F Prescott
Journal:  J Pharm Pharmacol       Date:  1973-07       Impact factor: 3.765

3.  Long-term treatment of ventricular arrhythmias with oral mexiletine.

Authors:  R G Talbot; D G Julian; L F Prescott
Journal:  Am Heart J       Date:  1976-01       Impact factor: 4.749

4.  Mexiletine (Kö 1173) in the management of ventricular dysrhythmias.

Authors:  N P Campbell; J G Kelly; R G Shanks; N C Chaturvedi; J E Strong; J F Pantridge
Journal:  Lancet       Date:  1973-08-25       Impact factor: 79.321
  4 in total
  2 in total

1.  Cediranib inhibits both the intraosseous growth of PDGF D-positive prostate cancer cells and the associated bone reaction.

Authors:  Abdo J Najy; Young Suk Jung; Joshua J Won; M Katie Conley-LaComb; Allen Saliganan; Chong Jai Kim; Elisabeth Heath; Michael L Cher; R Daniel Bonfil; Hyeong-Reh Choi Kim
Journal:  Prostate       Date:  2011-12-27       Impact factor: 4.104

Review 2.  Clinical pharmacokinetics of the newer antiarrhythmic agents.

Authors:  A M Gillis; R E Kates
Journal:  Clin Pharmacokinet       Date:  1984 Sep-Oct       Impact factor: 6.447
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.